In SCLC, SLFN11 expression correlated with PARPi olaparib and talazoparib activity in preclinical models, while it was associated with improved survival in patients treated with PARPi/chemotherapy combination (28, 42, 43). Here, SLFN11 is linked to small cell lung carcinoma.